|
|
Multiple Myeloma Update From the 51st Annual Meeting of the American Society of Hematology (ASH)
CME Information
|
|
|
|
Multiple myeloma is the second most prevalent blood cancer with in excess of 15 thousand new cases reported annually and recent statistics indicating increase incidence and earlier age of onset. For decades, there had been limited therapeutic advances for myeloma patients as the understanding of this disease slowly increased. More recently, there has been tremendous progress in the field of myeloma research and scientific advances now offer an unprecedented opportunity to treat myeloma patients. As new data emerge from clinical trials designed to improve upon current response rates, prolong survival, and minimize toxicities, it will be important to determine how these strategies may change current treatment guidelines and algorithms. Putting emerging clinical data into the context of whether or not these new data will affect current standards of care and allowing for expert analysis will assist physicians in making patient-tailored treatment decisions.
|
|
|
|
This activity has been designed to meet the educational needs of hematologists and oncologists involved in the management of patients with multiple myeloma. |
|
|
|
After completing this activity, the participant should be better able to: - Review clinical advancements in the treatment of patients with newly diagnosed myeloma.
- Describe the role of novel targeted therapies for treating patients with relapsed and refractory multiple myeloma.
- Review side effect profiles of new myeloma therapies.
- Review prevention strategies for treatment related toxicities.
|
|
|
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Multiple Myeloma Research Foundation (MMRF), Postgraduate Institute for Medicine (PIM), and cancereducation.com. PIM is accredited by the ACCME to provide continuing medical education for physicians.
|
|
|
|
Postgraduate Institute for Medicine designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim
credit commensurate with the extent of their participation in the activity. |
|
|
|
- Antonio Palumbo, MD
University of Turin
Torino, Italy
- Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ
|
|
|
|
Postgraduate Institute for Medicine (PIM) assesses conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity
Name of Faculty or Presenter |
Reported Financial Relationship |
 | |
Antonio Palumbo, MD |
Consulting Fees: Celgene
Fees for Non-CME Services: Celgene |
| |
Keith Stewart, MD |
Consulting Fees: Celgene, Genzyme, Novartis, Amgen
Contracted Research: Millennium |
| |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity
Name of Planner or Manager |
Reported Financial Relationship |
| |
Mark Altieri (cancereducation.com) |
No financial interest/relationships with financial interests relating to the topic of this activity
|
| |
Rich Parrish (cancereducation.com)
|
No financial interest/relationships with financial interests relating to the topic of this activity
|
| |
Anne Quinn Young, MPH (MMRF) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
Linda Graham, RN, BSN, BA (PIM) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
Jan Hixon, RN, BSN, MA (PIM) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
Trace Hutchison, PharmD (PIM) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
Julia Kirkwood, RN, BSN (PIM) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
Samantha Mattiucci, PharmD (PIM) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
Jan Schultz, RN, MSN, CCMEP (PIM) |
No financial interest/relationships with financial interests relating to the topic of this activity |
| |
|
|
|
|
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The Postgraduate Institute for Medicine (PIM), the Multiple Myeloma Research Foundation, cancereducation.com, Celgene Corporation, Millennium Pharmaceuticals, Inc., Bristol-Myers Squibb, and Merck & Co., Inc., do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, the Multiple Myeloma Research Foundation, cancereducation.com, Celgene Corporation, Millennium Pharmaceuticals, Inc., Bristol-Myers Squibb, and Merck & Co., Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
|
|
|
|
There are no fees for participating and receiving CME credit for this activity. During the period December 2009 through December 2010, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) Postgraduate Institute for Medicine will mail your certification of completion.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your
statement of credit will be mailed to you within three weeks.
|
|
|
|
Web
|
|
|
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
|
Click to continue
|
|